Vaxart - Bradac Co

ABOUT THE PROJECT

Vaxart focuses on the discovery and development of oral recombinant vaccines administered using temperature stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection, and potentially bringing life saving vaccinations to a wider audience world wide.

When Bradac Co started working with Vaxart, they were highly constrained by space and facility challenges, which were impacting productivity and growth. Bradac Co managed Vaxart’s renovation/tenant improvements of multiple lab and office spaces as they grew their campus to four locations in South San Francisco.

City : South San Francisco

Year : 2022

Size : 100,000 sf (multiple locations)

Team : DGA, Hathaway Dinwiddie

Photographer : Raymond Rudolph Photography

The new spaces included expanded employee workspaces, additional research labs and highly technical GMP pharmaceutical manufacturing testbed spaces, as well as warehouse and support space that included appropriate power and environmental criteria to support the safe storage of pharmaceutical materials.

Bradac Co worked closely with the architectural and contractor teams to ensure that the new spaces came online as quickly as possible without disrupting the client’s active facilities, including carefully orchestrating the move of existing equipment to new and expanded facilities with minimum downtime.